Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cell cultures from human prostate adenocarcinoma

GnRH analogs have antiproliferative and/or apoptotic effects on prostate cancer cells. Also, neurotrophin receptors TrkA and p75 have been reported in normal prostate suggesting a role in the gland growth control. In prostate cancer, TrkA receptors seem to be overexpressed and p75 receptors show a decreased expression. These changes in neurotrophin receptors may be related with unbalanced growth in malignant cells. In the present study we investigate the effects of GnRH analogs (leuprolide and cetrorelix) on the expression of TrkA and p75 neurotrophin receptors in primary cultures of human prostate cancer cells.

[1]  G. Nolan,et al.  Neurotrophin dependence domain , 2000, Journal of Molecular Neuroscience.

[2]  S. Byers,et al.  The p75NTR mediates a bifurcated signal transduction cascade through the NF kappa B and JNK pathways to inhibit cell survival. , 2005, Experimental cell research.

[3]  L. Sáenz,et al.  Secretion of prostatic specific antigen, proliferative activity and androgen response in epithelial-stromal co-cultures from human prostate carcinoma. , 2005, International journal of andrology.

[4]  Fatima S. Khwaja,et al.  Gene therapy of prostate xenograft tumors with a p75NTR lipoplex. , 2004, Anticancer research.

[5]  X. Montano,et al.  Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer , 2004, FEBS letters.

[6]  Javier Hernandez,et al.  Diagnosis and treatment of prostate cancer. , 2004, The Medical clinics of North America.

[7]  E. Small,et al.  Advances in prostate cancer. , 1999, Current opinion in oncology.

[8]  S. Hayward,et al.  Role of the stromal microenvironment in carcinogenesis of the prostate , 2003, International journal of cancer.

[9]  M. Motta,et al.  Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression. , 2003, Endocrine-related cancer.

[10]  D. Bredesen,et al.  Ten years on: mediation of cell death by the common neurotrophin receptor p75(NTR). , 2003, Cytokine & growth factor reviews.

[11]  Fatima S. Khwaja,et al.  The p75NTR tumor suppressor induces caspase‐mediated apoptosis in bladder tumor cells , 2003, International journal of cancer.

[12]  Fatima S. Khwaja,et al.  Inhibition of cell‐cycle effectors of proliferation in bladder tumor epithelial cells by the p75NTR tumor suppressor , 2003, Molecular carcinogenesis.

[13]  C. McArdle,et al.  Signalling and anti-proliferative effects mediated by gonadotrophin-releasing hormone receptors after expression in prostate cancer cells using recombinant adenovirus. , 2003, The Journal of endocrinology.

[14]  D. Djakiew,et al.  Neurotrophin receptor p75NTR suppresses growth and nerve growth factor‐mediated metastasis of human prostate cancer cells , 2002 .

[15]  D. Djakiew,et al.  Molecular characterization of the loss of p75NTR expression in human prostate tumor cells , 2001, Molecular carcinogenesis.

[16]  N. Singh,et al.  Microgels for estimation of DNA strand breaks, DNA protein crosslinks and apoptosis. , 2000, Mutation research.

[17]  A. Weeraratna,et al.  Rational basis for Trk inhibition therapy for prostate cancer , 2000, The Prostate.

[18]  L. Frati,et al.  Effects of triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP. , 2000, Journal of andrology.

[19]  D. Bostwick,et al.  High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. , 2000, The Journal of urology.

[20]  C. Vancheri,et al.  Mitogenic effect of nerve growth factor (NGF) in LNCaP prostate adenocarcinoma cells: role of the high- and low-affinity NGF receptors. , 2000, Molecular endocrinology.

[21]  Y. Wong,et al.  Growth factors and epithelial-stromal interactions in prostate cancer development. , 2000, International review of cytology.

[22]  M. Chao,et al.  Neurotrophin receptor structure and interactions. , 2000, Pharmaceutica Acta Helvetiae.

[23]  H. Kong,et al.  A comparison of the cytoplasmic domains of the Fas receptor and the p75 neurotrophin receptor , 1999, Cell Death and Differentiation.

[24]  Guate,et al.  Expression of p75LNGFR and Trk neurotrophin receptors in normal and neoplastic human prostate , 1999, BJU international.

[25]  S. Dirnhofer,et al.  Proliferative disorders of the aging human prostate: involvement of protein hormones and their receptors , 1999, Experimental Gerontology.

[26]  G. Sica,et al.  Effect of Leuprorelin Acetate on Cell Growth and Prostate-Specific Antigen Gene Expression in Human Prostatic Cancer Cells , 1998, European Urology.

[27]  D. Djakiew,et al.  Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor–induced cell growth by activation of programmed cell death , 1998, Molecular carcinogenesis.

[28]  A. Schally,et al.  Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines. , 1998, International journal of oncology.

[29]  D. Newling,et al.  Neurotrophic factors in prostate and prostatic cancer , 1998, Prostate Cancer and Prostatic Diseases.

[30]  D. Djakiew,et al.  Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial and stromal cells of the human prostate , 1997, Molecular and Cellular Endocrinology.

[31]  D. Djakiew,et al.  Loss of low‐affinity nerve growth factor receptor during malignant transformation of the human prostate , 1997, The Prostate.

[32]  M. Motta,et al.  Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. , 1996, The Journal of clinical endocrinology and metabolism.

[33]  B. Hempstead,et al.  p75 and Trk: A two-receptor system , 1995, Trends in Neurosciences.

[34]  D. Kaplan,et al.  Expression of a Trk high affinity nerve growth factor receptor in the human prostate. , 1995, Endocrinology.

[35]  M. Motta,et al.  Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. , 1994, Cancer research.

[36]  A. Schally,et al.  Responses to the antagonistic analog of LH‐RH (SB‐75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer , 1994, The Prostate.

[37]  D. Djakiew,et al.  Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines. , 1992, Cancer research.

[38]  M. Motta,et al.  Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. , 1992, The Journal of clinical endocrinology and metabolism.

[39]  D. Djakiew,et al.  Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. , 1992, The Journal of urology.

[40]  J. Isaacs,et al.  Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. , 1992, Cancer research.

[41]  G. Wilding The importance of steroid hormones in prostate cancer. , 1992, Cancer surveys.

[42]  M. Gleave,et al.  Human prostate cancer model: Roles of growth factors and extracellular matrices , 1992, Journal of cellular biochemistry. Supplement.

[43]  A. Schally,et al.  Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer. , 1992, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[44]  Martin R. Schneider,et al.  Effect of the new potent LHRH antagonist antide , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[45]  A. Schally,et al.  Receptors for luteinizing hormone‐releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia , 1989, The Prostate.

[46]  J. Minna,et al.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. , 1987, Cancer research.

[47]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.